MA-FORRESTER
25.6.2024 15:01:32 CEST | Business Wire | Press release
According to Forrester’s (Nasdaq: FORR) The Top 10 Emerging Technologies In 2024 report, generative AI (genAI) for visual content, genAI for language, TuringBots, and IoT security are the top emerging technologies that will deliver the most immediate ROI for businesses in 2024 and beyond.
With new technologies emerging seemingly every day, business and technology leaders need to time those investments based on value, risk, and potential payout timelines. Forrester organizes its top emerging technologies by benefit horizon to help with these decisions.
Emerging technologies that will offer significant benefits within the next two years:
- GenAI for visual content. Advanced machine learning models that generate images or video from text, audio, or video prompts, this technology will help firms generate visual content for marketing, experiences, and products.
- GenAI for language. GenAI for language is already delivering value in customer support and content creation but continues to advance at a blinding pace. It is accelerating many other technologies as it goes.
- TuringBots. Accelerated by advancements in genAI for language, these AI-powered software robots help developers build applications that deliver more than just code generation.
- IoT security. The proliferation of devices has led to an exponential explosion in security attacks, raising the importance of security for IoT devices. Vendors are competing and colliding in a rush to offer capabilities.
Midterm emerging technologies that will deliver benefits in the next two to five years:
- AI agents. The role of autonomous workplace assistants or AI agents has expanded beyond the back office and employee assistance to customer-facing automation. These AI agents will grow increasingly sophisticated to better understand and respond to nuance and context.
- Autonomous mobility. This technology will accelerate commercial and urban transportation ecosystem collaborations to orchestrate personalized mobility experiences for both customers and businesses.
- Edge intelligence. Advanced edge intelligence capabilities such as edge machine learning are still not yet common, even though many foundational elements like Apple foundation models are becoming available.
- Quantum security. This technology will overhaul security systems for on-premises and cloud compute, storage and network infrastructure, commercial off-the-shelf software, commercial software-as-a-service offerings, and in-house built software.
Emerging technologies that will take at least five more years to deliver tangible value for most firms and use cases:
- Extended reality (XR). Only 8% of US online adults own a virtual-reality headset, and just 16% have used an augmented-reality device or app. While XR is advancing in training and onboarding, companies are resisting investing in tools like these until they see broad adoption.
- Zero Trust edge (ZTE). ZTE technology has the potential to protect remote workers, retail outlets, and branch offices with embedded local security, but only a handful of true ZTE solutions exist today, and legacy devices add additional management complexity.
“Tech leaders must be able to identify the right use cases and quantify potential benefits, costs, and risks across multiple horizons,” says Brian Hopkins, Forrester VP, emerging tech portfolio. “They need to spread investments out, with shorter-term technologies delivering quick returns and longer-term bets requiring more effort, more foundational investment, and the capacity to manage more risk.”
Resources:
- Learn more about the top emerging technologies that will deliver ROI for enterprises.
- Read The Top 10 Emerging Technologies In 2024 report to gain insight into maturity trends, business value, important use cases, and risks associated with each technology (client access required).
- Register for a complimentary webinar that takes a deep dive into the 2024 list of emerging technologies and their use cases and benefits.
- Download Forrester’s complimentary guide for tech leaders to identify use cases and gain support for emerging technologies.
- Tech and data leaders can attend Forrester’s 2024 Technology & Innovation Summits in North America, EMEA, and Asia Pacific to learn how to align their IT strategy to their business goals to accelerate growth.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; more than 100 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625049417/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
